

# **COVID-19 and cancer services**

### **Report six**

Working report on the impact of COVID-19 on cancer services for the period ending October 2020

December 2020

### Contents

Contents	2
Summary of findings	3
Introduction	6
Lung Cancer Snapshot	7
Cancer Registrations	16
Gastrointestinal endoscopy	21
Combined curative cancer surgery	22
Colorectal cancer surgery	24
Prostate cancer surgery	25
Medical oncology	27
Radiation oncology	29
Haematology	32
Appendix 1: NZCR data information	35
Appendix 2: NZCR registrations by DHB	36
Appendix 3: Diagnosis and treatment data by DHB	39
Appendix 4: Surgical procedure codes	50

### **Summary of findings**

#### Overview of impact of COVID-19 on cancer diagnosis and treatment

There has now been the same number of new cancer diagnoses made in 2020 as were made in 2019. Cancer treatment services – surgery, medical oncology, radiation oncology and haematology – continued during the COVID-19 lockdown and continue to be delivered at pre-COVID volumes in the months since. In general, the COVID-19 response does not appear to have increased inequities in the cancer system. The concerning exception is lung cancer, where there has been a decrease in new diagnoses for Māori, with an increase for non-Māori.

#### **Background and data**

- This is the sixth report looking at the impact of COVID-19 on cancer services. This report looks at the period until the end of October 2020.
- The purpose of this analysis was to rapidly measure the impact of COVID-19 on cancer services to assist with recovery planning.
- The report focuses on the aspects of the cancer care pathway for which we have readily available data and does not capture all aspects of care.
- Comparisons between 2020 and 2019 do not consider any projected increase in diagnoses over time.
- The focus of the report was to understand the impact of COVID-19 on existing service delivery and does not address pre-existing unmet need.

#### Lung cancer snapshot

- This report includes a section focusing on lung cancer, as this was one area where inequity concerns had been raised in previous reports. There has been a 7.5% decrease in new diagnoses of lung cancer for Māori in 2020 compared to 2019. The same is not true for European/other, where there has been a stable 4.5% increase in lung cancer diagnoses over 2020.
- Given the overlap of the common presenting symptoms for COVID-19 and lung cancer there are several explanations for why lung cancer diagnoses may have decreased during COVID-19; however, most of these would be expected to impact all population groups equally. It is also possible that there are pathways by which Māori would be further disadvantaged during the COVID-19 pandemic, with exacerbation of existing barriers to diagnosis and treatment; however, this would be expected to be seen across all cancer types, not just lung cancer.
- In terms of routes to diagnosis, the number of people with lung cancer on the Faster Cancer Treatment pathway in 2020 remained stable for Māori. This means that the decrease in new diagnoses is likely to be for people diagnosed via other pathways.
  - We do not have readily available national data that looks at other pathways to presentation and whether these vary by ethnicity, although other work indicates that Māori are more likely to be diagnosed via the emergency department than non-Māori. If this pathway was disrupted during COVID-19 this could account for some of the disparity.
  - The COVID-19 response led to a decrease in hospital admissions for respiratory infections, which may have led to fewer incidental diagnoses of lung cancer. If a larger proportion of Māori are usually diagnosed through this pathway, then a disruption to this pathway could contribute to the observed decrease for Māori.
- Fewer bronchoscopies have been performed in 2020 than in 2019, with Māori having a larger decrease than non-Māori.

- We do not expect to see a complete catch up in bronchoscopies, as during the early stages of the pandemic people received other forms of investigation.
- Despite the inequity in new diagnoses, this does not appear to have translated into new inequities in treatment.
  - The difference in curative lung cancer surgeries for the year to date is similar for Māori to non-Māori/non-Pacific.
  - Lung cancer radiotherapy rates in 2020 appear to be similar to 2019, for both Māori and the populations as a whole.
- We need to ensure Māori with respiratory symptoms are appropriately investigated and diagnosed. The need is made more pressing by the risk of re-emergence of COVID-19, and the potential that clinical evaluation will be restricted to excluding a diagnosis of COVID-19. Te Aho o Te Kahu will continue to work with clinicians and COVID-19 response planners to look at how to address barriers to lung cancer diagnosis in the context of COVID-19, as well as continue broader work to improve the diagnostic pathways for Māori with lung cancer.

### **Cancer diagnosis**

#### Registrations

- For the year to date (up until the end of October 2020) there have been 104 more cancer registrations then during the same time period in 2019, a 0.4% increase. The cumulative number of cancer registrations in 2020 surpassed the number of registrations in 2019 in September.
- The increase in cancer registrations is similar for Māori (1.5%) and Pacific (1.3%) and, as seen in previous months, remains higher for the Asian ethnic group (9.1%). There remains a small (0.7%) decrease in new cancer registrations for European/other.
- The overall impact of COVID-19 on registrations for the year to date has been most marked for prostate, haematology/lymphoid and melanoma all have seen a 4-9% decrease overall across the population.

#### Diagnostics

- There has now been the same number of gastrointestinal endoscopies performed in 2020 compared to 2019. Given that at the end of May 2020 there were nearly 6000 (18%) fewer endoscopies performed than in 2019, this represents significant efforts to provide additional endoscopy services, including DHBs running longer clinics and weekend clinics.
- There has been a 5% increase in the number of endoscopies for Māori and a 13% increase for Pacific peoples in the first ten months of 2020 compared to the same time period in 2019.

### **Cancer Treatment**

#### Surgery

- Overall, the impact of COVID-19 on cancer surgery volumes has been minimal, with 2% more surgeries performed in the first ten months of 2020 compared to the first ten months of 2019. There has been a 21% increase in surgery for Māori for the first ten months of 2020 compared to the same time period in 2019.
- There has been a 21% decrease in surgeries for Pacific peoples, noting that this represents small numbers (23 fewer surgeries over ten months). This is an area Te Aho o Te Kahu will look into further.
- For the year to date there has been a 13% increase in prostate cancer surgeries compared to 2019. This is unexpected, given the 9.2% decrease in new diagnoses of prostate cancer in 2020.

#### Chemotherapy and radiotherapy

- **Medical oncology:** Overall, for the year to date the number of medical oncology FSAs and attendances for IV chemotherapy in 2020 is comparable to 2019.
- Radiation oncology: Overall for the year to date the number of radiation oncology FSAs in 2020 is comparable to 2019. For the year to date there has been an 8% decrease in attendances for radiation therapy. This is similar for Māori (7%) and non-Māori/non-Pacific (8%). This may, in part, be the result of national hypofractionation guidance<sup>1</sup>, and as such the number of attendances in 2020 may never reach the number of attendances in 2019.
- Haematology: Overall, for the year to date there has been a 3% decrease in haematology FSAs compared to the same time period in 2019. One contributor to this is likely to be a decrease in FSAs for non-malignant, non-urgent indications, deferred as part of the National Hospital Response Framework. These cases may have been effectively managed in primary care and so the number of FSAs in 2020 may never reach the number of FSAs in 2019. For the year to date there has been a 4% increase in IV chemotherapy for haematology compared to the same time period in 2019.

<sup>&</sup>lt;sup>1</sup> Hypofractionation is a radiation treatment technique used to treat some cancers, whereby larger doses of radiation are given at a time, meaning that people require fewer sessions to complete their treatment.

### Introduction

### Purpose of this report

This is the sixth report released by Te Aho o Te Kahu outlining the impact of COVID-19 on cancer services in New Zealand. This report looks at data through to the end of October 2020.

The report focuses on the aspects of the cancer care pathway for which we have readily available data and does not capture all aspects of care. Critical aspects of cancer care, including access to primary care, radiology and palliative care are not measured in this report.

### Data and analysis

The data in this report comes from Ministry of Health national data collections. Each section of the report includes information on where the data is from and any limitations with the data. Numbers in this report may not match previous reports exactly, due to late coding/submission of data. Te Aho o Te Kahu is actively working with DHBs to improve the accuracy and completeness of national collections data within the context of cancer.

It is important to note that the purpose of the analysis is to rapidly measure the impact of COVID-19 and the recovery on cancer services and does not consider pre-existing unmet need. The report also makes direct comparisons between 2020 and 2019 and does not consider any projected increase in diagnoses over time.

### Key dates

Key dates to 31 October 2020 in relation to COVID-19 that may be of use when reviewing the report include:

- 23 March: alert level 3 and hospital alert level framework released
- 26 March: alert level 4
- 28 April: alert level 3
- 14 May: alert level 2
- 9 June: alert level 1
- 12 August: alert level 3 Auckland, alert level 2 the rest of New Zealand
- 31 August: alert level 2.5 Auckland, rest of New Zealand stays at alert level 2
- 22 September: all regions, except Auckland, move to alert level 1
- 24 September: Auckland moves to alert level 2, without extra restrictions on travel and gatherings
- 8 October: all of New Zealand at alert level 1

### Lung Cancer Snapshot

Previous COVID-19 and Cancer reports have shown the continuing inequitable impact of COVID-19 on lung cancer diagnosis for Māori. This is of particular concern given the large inequities that already exist with lung cancer and the large and disproportionate burden of disease that lung cancer causes for Māori. It is also of interest, as lung cancer appears to be unique. Table 1 shows the percentage change in new diagnoses of cancer up until the end of October 2020 by cancer type, and shows that impact for Māori has generally been similar, or less severe, to European/other New Zealanders, with lung cancer being a notable exception.

	Māori	European/other
Breast	1.4	-5.3
Cervix	11.3	14
Colorectal	18.5	3.2
Endocrine	14.3	13.2
Gynaecology	0.7	2.1
Haematology and Lymphoid	-3.8	-7.2
Prostate	-10.3	-9.4
<b>Respiratory and thorax</b>	-7.5	4.5
Total	1.5	-0.7

Table 1: Percentage change in new diagnoses of cancer between 2020 and 2019 (up until the end ofOctober), by cancer type and ethnicity

This snapshot aims to: a) describe these inequities in detail, and b) consider what the potential drivers for these inequities are. As well as seeing if additional action is required, this will assist with planning in the event of resurgence of COVID-19 to make sure we do not see a similar pattern again.

#### Lung cancer registrations

Figure 1 shows the cumulative number of lung cancer registrations by year, for European/other and for Māori. This illustrates the decrease in lung cancer diagnoses for Māori, but not European/other, in 2020.




Figure 1: Cumulative number lung cancer registrations by year, European/other (left) and Māori (right)

Table 2 shows the number and percentage difference in lung cancer diagnoses at the end of each month in 2020 compared to 2019. By the end of October 2020 there had been a 4.5% **increase** in lung cancer diagnoses for European/other compared to 2019 (44 more cases). In contrast there has been a 7.5% **decrease** in lung cancer diagnoses for Māori in 2020 compared to 2019 (24 fewer cases). The largest gap in new diagnoses for Māori was seen in June-August, 2-3 months after the national lockdown. The 'gap' seems to be closing; however, this may be driven by a plateauing of cases in the last part of 2019 (seen in Figure 1).

	Europea	n/other	N	lāori
	Number	%	Number	%
Jan	10	10.6	8	27.6
Feb	7	3.4	-5	-8.2
Mar	10	3.2	-8	-8.4
Apr	-4	-1	-13	-10.2
May	11	2.2	-19	-11.7
Jun	34	5.8	-31	-15.7
Jul	49	7.2	-38	-16.3
Aug	33	4.2	-43	-15.9
Sep	44	5	-33	-11.1
Oct	44	4.5	-24	-7.5

Table 2: Absolute number and percentage change in cumulative lung cancer registrations to the end eachmonth in 2020 compared to 2019, by ethnicity

Table 3 shows data until the end of October, and presents the absolute number and percentage change in lung cancer registrations by DHB. This shows the inequity is larger in some DHBs than in others. The most notable decrease in registrations for Māori appears to have occurred in Auckland and Waikato DHBs.

### Table 3: Absolute number and percentage change in cumulative lung cancer registrations for the year to date (end of October) in 2020 compared to 2019, by DHB and ethnicity

	Europe	an/Other	M	āori
DHB	Number	%	Number	% <sup>2</sup>
Auckland	11	25	-10	-47.6
Bay of Plenty	-1	-1.9	-7	-20.6
Canterbury	18	14.5	8	
Capital & Coast	-13	-27.1	-4	-28.6
Counties Manukau	9	10.6	0	0
Hawke's Bay	9	25.7	-3	-13
Hutt Valley	1	3.7	-5	-45.5
Lakes	-1	-4.2	5	38.5
MidCentral	-20	-31.7	-1	-9.1
Nelson Marlborough	6	15	4	
Northland	10	24.4	5	16.7
South Canterbury	4	18.2	-2	
Southern	-10	-11.2	0	0
Tairāwhiti	0		2	
Taranaki	6	20	-5	
Waikato	15	17.9	-16	-30.8
Wairarapa	-4	-28.6	0	
Waitemata	2	1.6	1	5
West Coast	6	46.2	0	
Whanganui	-4	-16.7	4	

<sup>2</sup> Note: to avoid over interpretation of small numbers, percentages are only shown if the number of cases in 2019 exceeds ten.

### Diagnosis of lung cancer

#### Faster cancer treatment pathway: 62-day pathway referrals

If people are referred urgently to secondary care with a high suspicion of cancer, the aim is for them to receive their first treatment (or other management) within 62 days of the referral being received by the hospital. Patients on the 'faster cancer treatment pathway' are tracked, so that timing can be monitored and reported against.

In 2019, of the 1775 new diagnoses of lung cancer, there were 919 (52%) on the FCT pathway. This was a similar proportion for Māori, with 374 lung cancer diagnoses in 2019 and 198 (53%) on the FCT pathway.

Table 4 shows that in 2020 the overall proportion of lung cancer diagnoses on the FCT pathway is similar to 2019, although there was month-to-month variation particularly noticeable for Māori.

	Total Population	European/other	Māori
Jan	44%	53%	27%
Feb	48%	40%	84%
Mar	49%	52%	65%
Apr	65%	63%	61%
May	45%	46%	43%
Jun	50%	45%	79%
Jul	39%	44%	29%
Aug	58%	48%	82%
Sep	49%	53%	47%
TOTAL	49%	49%	55%


Table 4: Proportion of lung cancer diagnoses each month on the FCT pathway in 2020<sup>3</sup>

Figure 2 shows the number of referrals each month onto the 62-day FCT pathway. This shows a relatively stable number of referrals throughout the year. Figure 3 shows the cumulative number of referrals onto the FCT pathway, with the number of referrals in 2020 being very similar to 2019 for both the total population and for Māori.


Overall, there does not appear to have been a substantial change in FCT pathway diagnoses for Māori in 2020, suggesting that the 'missing' referrals for Māori are likely to be those diagnosed through alternative pathways. We do not have national data that is accessible in 'real time' to look at other pathways to presentation and whether these vary by ethnicity. Other pathways to diagnosis include through the emergency department, incidental findings either during a hospital admission or investigations for other reasons and diagnoses made as part of post-mortems.

<sup>&</sup>lt;sup>3</sup> Note: FCT data is only available until the end of September 2020.

### Figure 2: Number of 62-day pathway referrals for lung cancer, for total population (left) and for Māori (right)




### Figure 3: Cumulative number of 62-day pathway referrals for lung cancer, for total population (left) and for Māori (right)



#### Bronchoscopy


Figure 4 shows the number of bronchoscopies performed each month. This clearly demonstrates the impact of the pandemic, with a marked decrease in bronchoscopies performed in April 2020 – with this impact appearing to be greater for Māori. Of note, when the COVID-19 pandemic first emerged, bronchoscopies were considered extremely high-risk procedures and clinicians were encouraged to pursue an alternative form of investigation where possible e.g. CT guided biopsy.



#### Figure 4: Number of bronchoscopies by month and year, for the total population (left) and for Māori (right)

Figure 5 shows the cumulative number of bronchoscopies performed each year. Up until the end of October 2020 there had been a 15% decrease in bronchoscopies for non-Māori/non-Pacific (271 fewer scopes) compared to a 28% decrease for Māori (99 fewer scopes). It is important to note that a complete catch up is not expected, as during the early stages of the pandemic people would have received other forms of investigation.

### Figure 5: Cumulative number of bronchoscopies procedures by year, for the total population (left) and for Māori (right)




### **Treatment of lung cancer**

#### Lung cancer surgery

Figure 6 shows the number of curative lung cancer surgeries performed each month and Figure 7 shows the cumulative number of surgeries performed each year. In the first half of 2020 there was marked inequity in surgical procedures, but by the end of October there had been 8% fewer surgeries for non-Māori/non-Pacific (37 surgeries) and 7% fewer surgeries for Māori (7 surgeries).


This means that despite a persistent inequity in new diagnoses, this has not translated to persistent COVID-19-related inequities in access to cancer surgery.

### Figure 6: Number of curative lung cancer surgeries by month and year, total population (left) and for Māori (right)



\*Due to the small number of surgeries performed each month it is not possible to draw conclusions from small changes between months.

### Figure 7: Cumulative number of curative lung cancer surgeries by year, for the total population (left) and for Māori (right)




#### Radiation therapy: lung courses

Figure 8 shows that the cumulative number of lung cancer radiotherapy courses in 2020 is similar to 2019, for both the total population and for Māori. Given the decrease in new diagnose for Māori, this could mean:

- Radiotherapy made up a great proportion of treatment for Māori. It is possible that given the high-risk nature of lung cancer surgery (both from a COVID risk perspective and from the perspective of preserving ICU capacity) that there was a treatment modality shift, from surgery towards radiotherapy for Māori.
- Cancers were being diagnosed at a later stage when surgery was no longer an option and so radiotherapy became the default form of treatment.

### Figure 8: Cumulative number of lung cancer radiotherapy courses by year, for total population (left) and Māori (right)



### What is driving these inequities for Māori?

One of the challenges of diagnosing lung cancer in the context of the COVID-19 pandemic is that there is overlap of the common presenting symptoms for both COVID-19 and lung cancer. It is plausible that this would contribute to a decrease in new lung cancer diagnoses, as people with coughs and other respiratory symptoms stay home or seek medical care and receive a COVID-19 test rather than a more thorough workup of their symptoms. However, given that the decrease in lung cancer diagnoses was only seen for Māori we need to consider pathways by which there would be a disproportionate impact on Māori.

Around 50% of both Māori and non-Māori diagnosed with lung cancer are on the Faster Cancer Treatment pathway, and the number of people diagnosed on this pathway in 2020 seems to be comparable to 2019. Unfortunately, we do not have easily accessible national data that looks at the other pathways to diagnosis. A review of lung cancer diagnoses between 2015 and 2018 found that Māori were more likely to be diagnosed following an emergency department presentation compared to European/Other ethnicities (49% compared to 43% of diagnoses)<sup>4</sup>. During the COVID-19 pandemic it is possible that people who presented acutely and would usually have had a chest x-ray and other workup that might have picked up lung cancer, instead received a COVID-19 test. If this pathway is used more by Māori, then this could contribute to the drop in diagnosis.

Some diagnoses of lung cancer occur in the inpatient setting, when people are admitted for other reasons (e.g. respiratory infections). The COVID-19 lockdown response and social distancing virtually eliminated influenza from New Zealand<sup>5</sup> and there were fewer hospital admissions for other respiratory infections. This may have resulted in fewer incidental findings of lung cancer. Although this would likely impact all population groups, if a larger proportion of Māori are usually diagnosed through this pathway then a disruption to this pathway could contribute to the observed decrease in lung cancer diagnoses for Māori.

It is also possible to think of pathways by which Māori were further disadvantaged during the COVID-19 pandemic, with exacerbations of existing barriers to diagnoses and treatment. However, we would expect to see this across all cancer types, not just lung cancer, which was not the case. Similarly, we know that during the COVID-19 lockdown people with co-morbidities were being encouraged to stay home. Māori have higher rates of co-morbidity than non-Māori and so may have been more impacted by this advice. However, again this would have been expected to impact all cancer types, not just lung cancer, although it is possible that those with chronic respiratory co-morbidities related to smoking - and therefore also at higher risk of lung cancer – may have been additionally cautious.

There are additional challenges to diagnosis that have been identified by respiratory clinicians, including the difficultly of building relationships over the telephone and difficulty for those who had to travel to receive diagnostic tests. Some regions have seen a large increase in lung cancer presentations in the last 1-2 months, to the extent that at least one region has had to put on an additional lung cancer clinic each fortnight. Sadly, many of the recent diagnoses present at an advanced stage and on review symptoms first occurred during lockdown. Further qualitative work to understand the issues people experienced during lockdown will help shape a better response in the event of COVID-19 resurgence.

We need to ensure Māori with respiratory symptoms are appropriately investigated and diagnosed. The need is made more pressing by the risk of re-emergence of COVID-19, and the potential that clinical evaluation will be restricted to excluding a diagnosis of COVID-19. Te Aho o Te Kahu will continue to work with clinicians and COVID-19 response planners to look at how to address barriers to lung cancer diagnosis in the context of COVID-19, as well as continue broader work to improve the diagnostic pathways for Māori with lung cancer.

### **Key points**

- There has been a 7.5% decrease in new diagnoses of lung cancer for Māori in 2020 compared to 2019. The same is not true for European/other, where there has been a stable 4.5% increase in lung cancer diagnoses over 2020.
- Given the overlap of the common presenting symptoms for COVID-19 and lung cancer there are several explanations for why lung cancer diagnoses may have decreased during COVID-19; however, most of these would be expected to impact all population groups equally. It is also possible that there are pathways by which Māori would be further disadvantaged during the COVID-19 pandemic, with exacerbation of existing barriers to diagnosis and treatment; however, this would be expected to be seen across all cancer types, not just lung cancer.

<sup>&</sup>lt;sup>4</sup> Te Aho o Te Kahu, Lung Quality Performance Indicator Report – in publication

<sup>&</sup>lt;sup>5</sup> https://surv.esr.cri.nz/PDF\_surveillance/Virology/FluAnnRpt/InfluenzaAnn2020.pdf

- In terms of routes to diagnosis, the number of people with lung cancer on the Faster Cancer Treatment pathway in 2020 remained stable for Māori. This means that the decrease in new diagnoses is likely to be for people diagnosed via other pathways.
  - We do not have readily available national data that looks at other pathways to presentation and whether these vary by ethnicity, although other work indicates that Māori are more likely to be diagnosed via the emergency department than non-Māori. If this pathway was disrupted during COVID-19 this could account for some of the disparity.
  - The COVID-19 response led to a decrease in hospital admissions for respiratory infections, which may have led to fewer incidental diagnoses of lung cancer. If a larger proportion of Māori are usually diagnosed through this pathway, then a disruption to this pathway could contribute to the observed decrease for Māori.
- Fewer bronchoscopies have been performed in 2020 than in 2019, with Māori having a larger decrease than non-Māori.
  - We do not expect to see a complete catch up in bronchoscopies, as during the early stages of the pandemic people received other forms of investigation.
- Despite the inequity in new diagnoses, this does not appear to have translated into new inequities in treatment.
  - The difference in curative lung cancer surgeries for the year to date is similar for Māori to non-Māori/non-Pacific.
  - Lung cancer radiotherapy rates in 2020 appear to be similar to 2019, for both Māori and the populations as a whole.
- We need to ensure Māori with respiratory symptoms are appropriately investigated and diagnosed. The need is made more pressing by the risk of re-emergence of COVID-19, and the potential that clinical evaluation will be restricted to excluding a diagnosis of COVID-19. Te Aho o Te Kahu will continue to work with clinicians and COVID-19 response planners to look at how to address barriers to lung cancer diagnosis in the context of COVID-19, as well as continue broader work to improve the diagnostic pathways for Māori with lung cancer.

## National Data

### **Cancer Registrations**

#### Notes on data

- The data come from laboratory reports to the New Zealand Cancer Register (NZCR). This means that cancers diagnosed without haematology or pathology (e.g. radiology alone) will not be counted in this analysis.
- Data included in this report is provisional, and exact numbers may change as data is finalised.
- 'Date' is date of diagnosis on the NZCR usually the date the specimen was taken from the person and sent to the laboratory. Analyses include all new provisional and registered cancer events based on pathology and haematology reports. Data were extracted from NZCR on 21 November 2020.
- Further information on this data is included in Appendix 1.

#### Results


Table 5 shows the change in provisional cancer registrations in 2020 compared to 2019 by month, and the cumulative impact this has had on cancer registrations for the year to date (up until the end of October 2020).


Table 5: Absolute number and percentage change in cancer registrations in 2020 compared to 2019 by month, and cumulative year to date


	August 2	2020 September 2020		October 2020	Year to date		
	Number	%	Number	%	Number %	Number %	
Māori	26	10.3	52	21.4	32 12.7	38 1.5	
Pacific	12	15.4	2	2.1	11 12.9	12 1.3	
Asian	15	10.6	34	24.3	30 24.4	117 9.1	
European/Other	146	6.7	302	14.6	-86 -3.9	-151 -0.7	
Total Population	201	7.5	445	17.3	-2 -0.1	103 0.4	

Note: a small number of reports have 'unspecified' ethnicity, meaning the sum of all ethnic groups may not equal the total population.


### Figure 9: Total number of cancer registrations by month and year (left), cumulative number of cancer registrations by month and year (right)
















Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec





2018 — 2019 — 2020

2018 2019 2020


	August 2020		August 2020 Sept			er 2020	October	2020	Year to c	late*
Cancer Group	Number	%	Number	%	Number	%	Number	%		
Breast	35	10.1	75	20.9	-16	-3.9	-127	-3.6		
Cervix	-6	-3	138	97.9	68	40.5	272	16.3		
Colorectal	39	15.1	64	23.9	-2	-0.8	120	4.5		
Gynaecology	3	2.8	5	5.1	-2	-2.3	40	4.1		
Haematology and lymphoid	9	4.6	2	0.9	-7	-3.2	-106	-5.2		
Melanoma and non-melanoma skin	89	14.6	53	9.3	-86	-13.8	-229	-3.8		
Other digestive system	30	26.5	26	20.6	10	8.1	107	8.4		
Prostate	-49	-12.6	-39	-10.3	8	2.5	-304	-9.2		
Respiratory and thorax	-30	-17.9	34	25.2	8	5.6	26	1.8		
Urinary system	17	14.8	21	16.8	-1	-0.8	88	7.3		

Table 6: Changes in cancer registration for most common cancers in 2020 compared to 2019 by month and for the year to date, absolute difference in number of cases and percentage change, by cancer group

\*Note: this analysis uses provisional data for the 2020 registrations, some cancers may initially be classified as 'non-specified', and subsequently be re-classified into one of the cancer groups as more information is available.



#### Figure 12: Number of cancer registrations by month and year, by cancer group



#### Figure 13: Cumulative number of cancer registrations by year, by cancer group

Table 7: Changes in cancer registration in 2020 compared to 2019 by month and for the year to date, absolute difference in number of cases and percentage change, by DHB of domicile (see Appendix 2 for graphs)

	August 2020		Septembe	er 2020	October	2020	Year to date		
DHB	Number	%	Number	%	Number	%	Number	%	
Northland	33	29.5	37	37.4	-10	-7.6	51	4.5	
Waitemata	30	8.3	28	8	-18	-5.6	-1	0	
Auckland	60	27.3	24	10.2	19	8.8	53	2.3	
Counties Manukau	-6	-2.6	66	31.6	-7	-2.9	25	1.1	
Waikato	-3	-1.3	65	31.4	-3	-1.4	-7	-0.3	
Bay of Plenty	-3	-1.7	37	28.7	5	3.3	5	0.3	
Tairāwhiti	-6	-21.4	13	43.3	14	66.7	14	5.2	
Lakes	4	6.7	8	13.8	-8	-13.3	-18	-2.9	
Taranaki	-13	-15.7	10	12	19	25	3	0.4	
Hawke's Bay	-7	-6.9	21	21	0	0	-71	-7	
Whanganui	13	33.3	14	35	15	38.5	66	14.5	
MidCentral	2	1.6	24	22.2	-27	-19.4	54	5	
Capital & Coast	20	14.4	41	28.3	28	20.9	34	2.5	
Hutt Valley	29	39.7	4	5.5	5	6.4	28	3.7	
Wairarapa	15	51.7	12	50	-21	-47.7	28	10.3	
Nelson Marlborough	-14	-13.7	3	2.8	-38	-28.4	-57	-5.4	
West Coast	3	16.7	9	64.3	-2	-8.3	-8	-4	
Canterbury	18	6.3	-16	-5	5	1.7	-65	-2.2	
South Canterbury	-2	-5.4	-13	-31	0	0	-22	-5.9	
Southern	28	13.6	58	29.9	22	10.9	-9	-0.4	

#### **Key points**

- For the year to date (up until the end of October 2020) there have been 104 more cancer registrations then during the same time period in 2019, a 0.4% increase. The cumulative number of cancer registrations in 2020 surpassed the number of registrations in 2019 in September.
- The increase in cancer registrations is similar for Māori (1.5%) and Pacific (1.3%) and, as seen in previous months, remains higher for the Asian ethnic group (9.1%). There remains a small (0.7%) decrease in new cancer registrations for European/other.
- The overall impact of COVID-19 on registrations for the year to date has been most marked for prostate, haematology/lymphoid and melanoma all have seen a 4-9% decrease.

### **Gastrointestinal endoscopy**

#### Notes on data


- Gastrointestinal endoscopy data were extracted from National Non-admitted Patient Collection (outpatient) and National Minimum Dataset (inpatient) on 28 November 2020.
- Includes colonoscopies and gastroscopies for all indications (i.e. not just cancer).
- Technical information: Gastroscopies (Purchase Unit Code MS02005), Colonoscopies (Purchase Unit Code MS02007), Combined Gastroscopies + Colonoscopies (Purchase Unit Code MS02014).

#### Results


Table 8: Absolute number and percentage change in colonoscopy and gastroscopy in 2020 compared to2019 by month, and cumulative year to date

	August 2020		Septembe	r 2020	Octobe	r 2020	Year to	Year to date	
	Number	%	Number	%	Number	%	Number	%	
Māori	26	4%	143	22%	135	21%	306	5%	
Pacific peoples	-4	-2%	21	9%	41	18%	286	13%	
Non-Māori/Non-Pacific	277	4%	437	7%	368	6%	-592	-1%	
Total Population	299	4%	601	9%	544	8%	0	0%	

Figure 14: Number of gastrointestinal endoscopy procedures by month and year, for the total population (left) and for Māori (right)



### Figure 15: Cumulative number of gastrointestinal endoscopy procedures by year, for the total population (left) and for Māori (right)



### **Key points**

- There has now been the same number of gastrointestinal endoscopies performed in 2020 compared to 2019. Given that at the end of May 2020 there were nearly 6000 (18%) fewer endoscopies performed than in 2019, this represents significant efforts to provide additional endoscopy services, including DHBs running longer clinics and weekend clinics.
- There has been a 5% increase in the number of endoscopies for Māori and a 13% increase for Pacific peoples in 2020 compared to 2019.

### **Combined curative cancer surgery**

#### Notes on data

- This report includes data on curative surgery for colorectal, lung and prostate cancer. These cancers were chosen because a pre-validated list of surgical procedure codes for these cancers already existed within Te Aho o Te Kahu, agreed on as part of the quality performance indicator work programme. These three cancers are therefore used as case studies for cancer surgery more generally. The procedure codes are included in Appendix 4.
- Note: lung cancer surgery data has been included under the lung cancer snapshot (see page 7).
- The data was extracted from the National Minimum Dataset on 28 November 2020.


#### Results

Table 9: Absolute number and percentage change in curative surgery (colorectal, lung and prostate) in2020 compared to 2019 by month, and cumulative year to date


	August 2020		September 2020		October 2	2020	Year to date	
	Number	%	Number	%	Number	%	Number	%
Māori	7	29%	0	0%	11	32%	68	21%
Pacific peoples							-23	-21%
Non-Māori/Non-Pacific	24	8%	5	2%	30	11%	8	0%
Total Population	29	8%	6	2%	39	12%	53	2%

\*Due to small numbers, monthly figures have not been included for Pacific peoples

### Figure 16: Number of curative cancer surgeries (prostate, colorectal, lung) by month and year, for the total population (left) and for Māori (right)



### Figure 17: Cumulative number of curative cancer surgeries (colorectal, lung, prostate) by year, for the total population (left) and for Māori (right)



### **Key points**

- Overall, the impact of COVID-19 on cancer surgery volumes has been minimal, with 2% more surgeries performed in the first ten months of 2020 compared to the first ten months of 2019. There has been an 21% increase in surgery for Māori in 2020 compared to 2019.
- There has been a 21% decrease in surgeries for Pacific peoples, noting that this represents small numbers (23 fewer surgeries over ten months).

### **Colorectal cancer surgery**

#### Notes on data

- A list of the surgical procedure codes used for analysis are included in Appendix 4.
- The data were extracted from the National Minimum Dataset on 28 November 2020.


#### Results

Table 10: Absolute number and percentage change in curative colorectal cancer surgery in 2020 compared to 2019 by month, and cumulative year to date


_	August 2020		September 2020		October 2	020	Year to date	
	Number	%	Number	%	Number	%	Number	%
Māori	2	17%	2	10%	4	24%	65	40%
Pacific peoples	-2		-1		3		-17	-27%
Non-Māori/Non-Pacific	28	14%	13	7%	34	20%	-32	-2%
Total Population	28	13%	14	7%	41	21%	16	1%

\*Due to small numbers, monthly figures have not been included for Pacific peoples

### Figure 18: Number of curative colorectal cancer surgeries by month and year, for the total population (left) and for Māori (right)



### Figure 19: Cumulative number of curative colorectal cancer surgeries by year, for the total population (left) and for Māori (right)



#### **Key points**

• There has been a 1% increase in curative colorectal cancer surgeries in 2020 compared to 2019. This includes a 40% increase in surgeries for Māori in the first ten months of 2020 compared to the first ten months of 2019.

### **Prostate cancer surgery**

#### Notes on data

- A list of the surgical procedure codes used for analysis are included in Appendix 4.
- The data was extracted from the National Minimum Dataset on 28 November 2020.
- The number of curative prostate cancer surgeries performed each month is relatively small, so caution is needed when comparing data by month.


#### Results

Table 11: Absolute number and percentage change in curative prostate cancer surgery in 2020 comparedto 2019 by month, and cumulative year to date

	August 2020		September 2020		October 2020		Year to date	
	Number	%	Number	%	Number	%	Number	%
Total Population	8	11%	-4	-6%	8	12%	82	13%


\*Due to the small number of surgeries performed each month calculations have only been included for the total population

### Figure 20: Number of curative prostate cancer surgeries by month and year, total population (left) and for Māori (right)



\*Due to the small number of surgeries performed each month it is not possible to draw conclusions from small changes between months.

### Figure 21: Cumulative number of curative prostate cancer surgeries by year, for the total population (left) and for Māori (right)



### **Key points**

- For the year to date there has been a 13% increase in prostate cancer surgeries compared to 2019.
  - This is unexpected, given the 9.2% decrease in new diagnoses of prostate cancer in 2020.

### **Medical oncology**

#### Notes on data


- Data were extracted from National Non-admitted Patient Collection (outpatient collection) on 28 November 2020.
- First specialist assessment (FSA) reflects counts of first attendance for specialist medical oncology assessment.
- IV chemotherapy reflects appointments for outpatient and inpatient IV chemotherapy for nonhaematological indications.
- Technical information: medical oncology FSA (PUC M50020), and IV chemotherapy (PUC MS02009)

### Results

Table 12: Absolute number and percentage change in medical oncology first specialist assessments in 2020compared to 2019 by month, and cumulative year to date

	August 2020		September 2020		October 2020		Year to date	
	Number	%	Number	%	Number	%	Number	%
Māori	-20	-14%	-13	-11%	16	16%	-34	-3%
Pacific peoples	8	20%	11	33%	0	0%	53	15%
Non-Māori/Non-Pacific	-38	-6%	-21	-3%	23	4%	43	1%
Total Population	-50	-6%	-23	-3%	39	6%	62	1%

### Figure 22: Number of medical oncology first specialist assessments by month and year, for the total population (left) and for Māori (right)



### Figure 23: Cumulative number of medical oncology first specialist assessments by year, for the total population (left) and for Māori (right)







Table 13: Absolute number and percentage change in IV chemotherapy attendances in 2020 compared to2019 by month, and cumulative year to date

	August 2020		September 2020		October 2020		Year to date	
	Number	%	Number	%	Number	%	Number	%
Māori	20	2%	29	3%	-164	-19%	717	9%
Pacific peoples	-1	0%	7	2%	-54	-16%	7	0%
Non-Māori/Non-Pacific	-189	-3%	135	3%	-882	-16%	-489	-1%
Total Population	-170	-3%	171	3%	-1100	-16%	235	0%





### Figure 25: Cumulative number of attendances for IV chemotherapy by year, for the total population (left) and for Māori (right)



### **Key points**

• Overall, for the year to date the number of medical oncology FSAs and attendances for IV chemotherapy in 2020 is comparable to 2019.

### **Radiation oncology**

#### Notes on data

- Data were extracted from the National Non-admitted Patient Collection on 28 November 2020.
- First specialist assessment (FSA) reflects counts of first attendance for radiation oncology specialist assessment.
- Megavoltage attendance reflects appointments for planning/simulation and for treatment with radiation therapy on a linear accelerator.
- Technical information: radiation oncology FSA (PUC M50022), megavoltage attendances (Purchase Unit Code M50025)

#### Results

 Table 14: Absolute number and percentage change in radiation oncology first specialist assessments in

 2020 compared to 2019 by month, and cumulative year to date

	August 2020		September 2020		October 2020		Year to date	
	Number	%	Number	%	Number	%	Number	%
Māori	-31	-22%	3	2%	-26	-18%	18	1%
Pacific peoples	-6	-12%	8	22%	-14	-26%	-46	-10%
Non-Māori/Non-Pacific	-17	-2%	63	8%	-120	-14%	-105	-1%
Total Population	-54	-5%	74	7%	-160	-15%	-133	-1%

### Figure 26: Number of radiation oncology first specialist assessments by month and year, total population (left) and for Māori (right)




Figure 27: Cumulative number of radiation oncology first specialist assessments by month and year, total population (left) and for Māori (right)




Table 15: Absolute number and percentage change in radiation therapy attendances in 2020 compared to2019 by month, and cumulative year to date

	August 2020		September 2020		October 2020		Year to date	
	Number	%	Number	%	Number	%	Number	%
Māori	117	7%	-58	-3%	-462	-24%	-1211	-7%
Pacific peoples	-27	-5%	77	13%	-145	-21%	-65	-1%
Non-Māori/Non-Pacific	-1548	-14%	-435	-4%	-1692	-15%	-8999	-8%
Total Population	-1458	-11%	-416	-3%	-2299	-17%	-10275	-8%

### Figure 28: Number of attendances for radiation therapy by month and year, total population (left) and for Māori (right)





Figure 29: Cumulative number of attendances for radiation therapy by month and year, total population (left) and for Māori (right)



### **Key points**

- Overall, for the year to date the number of radiation oncology FSAs in 2020 is comparable to 2019.
- For the year to date there has been an 8% decrease in attendances for radiation therapy. This is
  similar for Māori (7%) and non-Māori/non-Pacific (8%). This may, in part, be the result of national
  hypofractionation guidance, and as such the number of attendances in 2020 may never reach the
  number of attendances in 2019.

### Haematology

#### Notes on data


- Data were extracted from the National Non-admitted Patient Collection (outpatient) and National Minimum Dataset (inpatient) 28 November 2020.
- First specialist assessment (FSA) reflects counts of first attendance for specialist haematology assessment for any indication (i.e. not just cancer).
- IV chemotherapy reflects appointments for IV chemotherapy for haematological malignancies.
- Technical information: Haematology FSA (Purchase Unite Code M30002), IV haem/chemo (Purchase Unit Code M30020).

#### Results

Table 16: Absolute number and percentage change in haematology FSAs in 2020 compared to 2019 by month, and cumulative year to date

	August 2020		September 2020		October 2020		Year to date	
	Number	%	Number	%	Number	%	Number	%
Māori	10	18%	19	33%	12	21%	26	4%
Pacific peoples	14	64%	5	19%	-7	-23%	15	6%
Non-Māori/Non-Pacific	-13	-3%	48	11%	29	6%	-212	-5%
Total Population	11	2%	72	14%	34	6%	-171	-3%

Figure 30: Number of haematology first specialist assessments by month and year, total population (left) and for Māori (right)



### Figure 31: Cumulative number of haematology first specialist assessments by month and year, total population (left) and for Māori (right)








 Table 17: Absolute number and percentage change in IV chemotherapy attendances for haematological malignancies in 2020 compared to 2019 by month, and cumulative year to date

	August 2020		September 2020		October 2020		Year to date	
	Number	%	Number	%	Number	%	Number	%
Māori	-41	-16%	12	5%	-31	-13%	-69	-3%
Pacific peoples	66	65%	71	86%	96	113%	424	49%
Non-Māori/Non-Pacific	-152	-8%	237	13%	-139	-7%	436	3%
Total Population	-127	-6%	320	15%	-74	-3%	791	4%









#### **Key points**

- Overall, for the year to date there has been a 3% decrease in haematology first specialist appointments compared to the same time period in 2019. One contributor to this is likely to be a decrease in FSAs for non-malignant, non-urgent indications, deferred as part of the hospital response framework. These cases may have been effectively managed in primary care and so the number of FSAs in 2020 may never reach the number of FSAs in 2019.
- For the year to date there has been a 4% increase in IV chemotherapy for haematology compared to the same time period in 2019.

### **Appendix 1: NZCR data information**

## The New Zealand Cancer Registry as a source of data for new cancer diagnoses

Cancer registration is a process where data is collated from multiple sources about people diagnosed with cancer and rules are applied to determine the type of cancer they have. This information is recorded in the New Zealand Cancer Registry. Each tumour is classified using an international World Health Organisation standard so that cancer incidence can be compared between countries. The tumour is staged based on all the information available within 4 months of diagnosis. This process may take up to six months or more depending on the number of missing reports that need to be followed up with laboratories.

For each registration there may be multiple pathology reports as there may be multiple procedures performed on the tumour. This means there will be more than one registration for people diagnosed with more than one type of tumour.


Cancer registrations come from pathology laboratories, haematology laboratories, mortality records and reviewing hospital discharge records. Laboratory reports provide the best source of near real time data to monitor new diagnoses of cancer in New Zealand.

## Pathology reports as a data source for providing near real time monitoring cancer diagnoses


Pathology reports (documents) are received by the NZCR as electronic messages. An administrator triages these documents each day and if the document appears to meet the requirements for registration the document is "administered". The document may relate to an existing registration or may contain information for a new cancer event. Documents that do not meet the cancer reporting requirements will be marked as "deleted", "rejected" or "agreed not for registration".

The administrator creates a new provisional cancer event if the pathology report identifies a new cancer diagnosis for this person. This new cancer event is assigned to a cancer group and this provisional event is then queued for further assessment by a clinical coder. If the required information has been provided the coder creates a new registration. If some information is not yet available, then the registration is held open until further information arrives to complete the registration or determine that the tumour does not meet the registration criteria.

### **Appendix 2: NZCR registrations by DHB**



2018 2019 2020



— 2018 — 2019 **—** 2020

## **Cancer Registrations by DHB**

		То	tal Popu	lation					Māo	ri				Eu	iropean	/Other	
		lative nu Jan to (		Differe between and 20	2019	_		lative nu <sup>-</sup> Jan to (		Differ betweer and 2	า 2019	_		lative nu Jan to (		Differei between and 20	2019
	2018	2019	2020	Number	%		2018	2019	2020	Number	%		2018	2019	2020	Number	%
Northland	1143	1137	1188	51	4.5		258	208	247	39	18.8	Γ	866	901	917	16	1.8
Waitemata	3196	3301	3300	-1	0		161	186	206	20	10.8		2610	2672	2569	-103	-3.9
Auckland	2337	2280	2333	53	2.3		117	123	114	-9	-7.3		1739	1630	1678	48	2.9
Counties Manukau	2167	2277	2302	25	1.1		237	267	307	40	15		1326	1329	1327	-2	-0.2
Waikato	2413	2242	2235	-7	-0.3		356	327	302	-25	-7.6		1938	1810	1796	-14	-0.8
Bay of Plenty	1469	1515	1520	5	0.3		219	241	229	-12	-5		1222	1234	1254	20	1.6
Tairāwhiti	244	269	283	14	5.2		80	91	104	13	14.3		162	172	171	-1	-0.6
Lakes	511	623	605	-18	-2.9		119	146	159	13	8.9		368	444	417	-27	-6.1
Taranaki	766	766	769	3	0.4		81	73	77	4	5.5		667	684	670	-14	-2
Hawke's Bay	1012	1011	940	-71	-7		157	165	150	-15	-9.1		817	807	753	-54	-6.7
Whanganui	476	455	521	66	14.5		71	78	68	-10	-12.8		397	364	436	72	19.8
MidCentral	1170	1077	1131	54	5		127	99	118	19	19.2		993	934	954	20	2.1
Capital & Coast	1447	1378	1412	34	2.5		104	109	117	8	7.3		1161	1115	1123	8	0.7
Hutt Valley	742	752	780	28	3.7		92	105	80	-25	-23.8		585	567	622	55	9.7
Wairarapa	295	272	300	28	10.3		31	21	32	11	52.4		257	244	257	13	5.3
Nelson Marlborough	1006	1050	993	-57	-5.4		54	50	41	-9	-18		926	967	918	-49	-5.1
West Coast	182	200	192	-8	-4		20	15	11	-4	-26.7		161	180	179	-1	-0.6
Canterbury	2753	2892	2827	-65	-2.2		160	149	145	-4	-2.7		2411	2578	2486	-92	-3.6
South Canterbury	342	374	352	-22	-5.9		17	18	13	-5	-27.8		312	352	328	-24	-6.8
Southern	1821	2010	2001	-9	-0.4		87	114	103	-11	-9.6		1683	1833	1811	-22	-1.2

## **Appendix 3: Diagnosis and treatment data by DHB**

Percentage differences are only presented if the cumulative 2019 total is 10 or greater. In some cases, the grand totals may differ slightly to those presented in the national report. This is due to non-DHB providers being excluded from the analyses within this appendix.

#### **Gastrointestinal endoscopy**

		Tot	tal popula	ation				Māo	ori				Non-M	lāori / No	n-Pacific	
		ative num Jan to Oct		Differ betweer and 2	n 2019		llative nu r Jan to C		Differe between 20 2020	019 and	Cu		ative num Jan to Oct		Differe betweer and 2	n 2019
	2018	2019	2020	Number	%	2018	2019	2020	Number	%	20	18	2019	2020	Number	%
Northland	3157	3271	3099	-172	-5%	534	641	587	-54	-8%	26	605	2602	2485	-117	-4%
Waitemata	7162	8184	8025	-159	-2%	400	481	448	-33	-7%	65	13	7449	7226	-223	-3%
Auckland	5112	5314	5031	-283	-5%	284	256	301	45	18%	44	79	4697	4335	-362	-8%
Counties Manukau	7344	7966	8038	72	1%	723	769	816	47	6%	57	43	6165	6106	-59	-1%
Waikato	4350	5490	5615	125	2%	526	663	655	-8	-1%	37	'59	4764	4884	120	3%
Bay of Plenty	4130	4112	4284	172	4%	477	520	574	54	10%	36	32	3573	3694	121	3%
Lakes	1639	1649	1613	-36	-2%	293	306	323	17	6%	13	22	1319	1263	-56	-4%
Tairāwhiti	567	709	621	-88	-12%	160	210	186	-24	-11%	40	04	493	426	-67	-14%
Taranaki	1631	1545	1777	232	15%	159	161	153	-8	-5%	14	63	1377	1610	233	17%
Whanganui	714	564	1105	541	96%	108	74	162	88	119%	60	05	482	934	452	94%
Hawke's Bay	2038	2491	2543	52	2%	233	315	358	43	14%	17	83	2145	2146	1	0%
MidCentral	1754	1924	1912	-12	-1%	128	147	169	22	15%	16	808	1760	1718	-42	-2%
Capital & Coast	2419	2290	2787	497	22%	189	142	223	81	57%	21	.38	2048	2466	418	20%
Hutt Valley	1938	2478	2777	299	12%	178	195	290	95	49%	16	83	2206	2387	181	8%
Wairarapa	830	889	780	-109	-12%	74	79	74	-5	-6%	74	47	804	701	-103	-13%
Nelson Marlborough	1425	2296	2302	6	0%	67	125	135	10	8%	13	47	2162	2149	-13	-1%
West Coast	593	531	574	43	8%	44	35	26	-9	-26%	54	47	493	544	51	10%
Canterbury	4799	7932	6900	-1032	-13%	275	466	401	-65	-14%	44	57	7349	6401	-948	-13%
South Canterbury	1019	1068	969	-99	-9%	41	36	50	14	39%	97	75	1029	917	-112	-11%
Southern	3797	4136	4087	-49	-1%	160	234	230	-4	-2%	36	609	3876	3809	-67	-2%
Total	56418	64839	64839	0	0%	5053	5855	6161	306	5%	494	419	56793	56201	-592	-1%

## Bronchoscopy

		Т	otal popu	ulation				Māo	ri			Non-I	Māori / N	Ion-Pacific	
		llative nu r Jan to C		Differer between 20 2020	)19 and		nulative nu for Jan to (		Differe between 20 2020	)19 and		ulative nu r Jan to (		Differe between 20 2020	019 and
	2018	2019	2020	Number	%	2018	2019	2020	Number	%	2018	2019	2020	Number	%
Northland	64	72	63	-9	-13%	21	19	22	3	16%	42	52	40	-12	-23%
Waitemata	117	119	123	4	3%	7	6	11	5	-	103	108	106	-2	-2%
Auckland	279	344	250	-94	-27%	40	45	27	-18	-40%	208	272	203	-69	-25%
Counties Manukau	294	309	271	-38	-12%	55	52	36	-16	-31%	201	203	194	-9	-4%
Waikato	223	233	176	-57	-24%	47	55	34	-21	-38%	171	175	138	-37	-21%
Bay of Plenty	127	155	110	-45	-29%	27	38	26	-12	-32%	98	115	84	-31	-27%
Lakes	73	76	71	-5	-7%	27	24	24	0	0%	45	51	44	-7	-14%
Tairāwhiti	2	8	22	14	-	1	3	10	7	-	1	5	12	7	-
Taranaki	40	56	37	-19	-34%	9	8	4	-4	-	31	48	33	-15	-31%
Whanganui	3	3	11	8	-	0	2	5	3	-	3	1	6	5	-
Hawke's Bay	58	50	38	-12	-24%	15	11	8	-3	-27%	41	37	29	-8	-22%
MidCentral	39	28	23	-5	-18%	4	9	2	-7	-	35	19	21	2	11%
Capital & Coast	84	76	59	-17	-22%	8	9	8	-1	-	70	65	49	-16	-25%
Hutt Valley	80	110	75	-35	-32%	11	25	12	-13	-52%	64	83	58	-25	-30%
Nelson Marlborough	63	62	71	9	15%	4	6	6	0	-	59	56	64	8	14%
Canterbury	278	362	305	-57	-16%	16	30	18	-12	-40%	259	327	281	-46	-14%
South Canterbury	13	12	15	3	25%	0	1	0	-1	-	13	11	15	4	36%
Southern	210	188	157	-31	-16%	18	17	8	-9	-53%	192	168	148	-20	-12%
Total	2047	2263	1877	-386	-17%	310	360	261	-99	-28%	1636	1796	1525	-271	-15%

## **Colorectal cancer surgery**

		Тс	otal popu	llation				Māc	ori			Non-I	Māori / N	Ion-Pacific	
		ative num Ian to Oc		Differe between 20 2020	019 and		llative nu r Jan to C		Difference 2019 and			lative nu r Jan to C		Differe between 20 2020	019 and
_	2018	2019	2020	Number	%	2018	2019	2020	Number	%	2018	2019	2020	Number	%
Northland	63	85	70	-15	-18%	10	18	16	-2	-11%	53	66	53	-13	-20%
Waitemata	200	220	180	-40	-18%	11	15	11	-4	-27%	183	190	166	-24	-13%
Auckland	168	154	171	17	11%	10	11	19	8	73%	139	125	143	18	14%
Counties Manukau	132	103	121	18	17%	8	8	16	8	-	107	86	88	2	2%
Waikato	205	170	235	65	38%	26	16	35	19	119%	175	151	199	48	32%
Bay of Plenty	114	112	158	46	41%	14	10	25	15	150%	100	101	133	32	32%
Lakes	57	63	65	2	3%	10	10	9	-1	-10%	46	51	55	4	8%
Tairāwhiti	18	23	25	2	9%	7	4	8	4	-	11	19	17	-2	-11%
Taranaki	79	67	72	5	7%	7	4	9	5	-	72	63	63	0	0%
Whanganui	40	39	45	6	15%	6	5	3	-2	-	34	34	42	8	24%
Hawke's Bay	115	123	126	3	2%	17	8	18	10	-	98	114	104	-10	-9%
MidCentral	113	80	100	20	25%	6	6	12	6	-	106	73	87	14	19%
Hutt Valley	56	60	46	-14	-23%	4	8	3	-5	-	50	52	42	-10	-19%
Wairarapa	21	16	5	-11	-69%	2	1	0	-1	-	19	15	5	-10	-67%
Capital & Coast	132	133	114	-19	-14%	14	9	13	4	-	112	117	98	-19	-16%
Nelson Marlborough	74	77	59	-18	-23%	0	6	4	-2	-	74	70	55	-15	-21%
West Coast	1	6	8	2	-	-	-	-	-	-	1	6	8	2	-
Canterbury	249	271	253	-18	-7%	14	13	17	4	31%	232	256	233	-23	-9%
South Canterbury	45	42	37	-5	-12%	0	2	2	0	-	45	40	35	-5	-13%
Southern	202	230	200	-30	-13%	8	7	6	-1	-	193	220	191	-29	-13%
Total	2084	2074	2090	16	1%	174	161	226	65	40%	1850	1849	1817	-32	-2%

#### Lung cancer surgery

		T	otal pop	ulation				Māo	ri			Non-I	Māori / N	Non-Pacific	
		ilative nu an to Oct		Differen between 20 2020			ulative nu an to Oct		Differer between 20 2020	19 and		ulative nu an to Oct		Differer between 20 2020	19 and
	2018	2019	2020	Number	%	2018	2019	2020	Number	%	2018	2019	2020	Number	%
Auckland	249	248	217	-31	-13%	45	49	41	-8	-16%	188	178	158	-20	-11%
Counties Manukau	1	2	2	0	-	0	0	1	1	-	0	2	1	-1	-
Waikato	102	116	128	12	10%	33	28	29	1	4%	66	88	98	10	11%
Taranaki	1	0	0	0	-	-	-	-	-	-	1	0	0	0	-
Hawke's Bay	0	0	1	1	-	0	0	0	0	-	-	-	-	-	-
Capital & Coast	95	114	81	-33	-29%	23	19	12	-7	-37%	69	90	66	-24	-27%
Canterbury	68	77	95	18	23%	6	4	7	3	-	62	73	86	13	18%
Southern	34	41	29	-12	-29%	4	1	4	3	-	30	40	25	-15	-38%
Total	550	598	553	-45	-8%	111	101	94	-7	-7%	416	471	434	-37	-8%

## Prostate cancer surgery

		Т	otal pop	ulation				Māor	i			Non	Māori /	Non-Pacific	
		ilative nu an to Oct		Differe between 20 2020	019 and		ulative nu Jan to Oc		Differer between and 20	2019		nulative n r Jan to Oc		Differe between 20 2020	019 and
	2018	2019	2020	Number	%	2018	2019	2020	Number	%	201	8 2019	2020	Number	%
Northland	47	46	30	-16	-35%	9	5	6	1	-	38	40	24	-16	-40%
Waitemata	67	62	88	26	42%	2	5	5	0	-	62	56	80	24	43%
Auckland	70	88	110	22	25%	3	11	11	0	0%	63	66	93	27	41%
Counties Manukau	0	1	2	1	-	0	0	1	1	-	0	1	1	0	-
Waikato	59	48	48	0	0%	2	3	3	0	-	56	45	44	-1	-2%
Bay of Plenty	41	42	36	-6	-14%	4	7	5	-2	-	37	35	31	-4	-11%
Lakes	6	9	15	6	-	0	0	7	7	-	5	9	8	-1	-
Tairāwhiti	4	3	6	3	-	1	2	2	0	-	3	1	4	3	-
Taranaki	20	25	28	3	12%	1	3	5	2	-	18	22	23	1	5%
Whanganui	3	4	5	1	-	1	0	0	0	-	2	4	5	1	-
Hawke's Bay	14	15	22	7	47%	0	3	5	2	-	14	12	17	5	42%
MidCentral	60	66	68	2	3%	2	9	4	-5	-	58	57	64	7	12%
Capital & Coast	50	58	59	1	2%	3	3	4	1	-	43	52	53	1	2%
Nelson Marlborough	42	33	37	4	12%	-	-	-	-	-	42	32	37	5	16%
Wairarapa	8	6	7	1	-	1	0	1	1	-	7	6	6	0	-
West Coast	8	4	6	2	-	0	0	0	0	-	8	4	6	2	-
Canterbury	61	48	60	12	25%	0	2	3	1	-	61	46	56	10	22%
South Canterbury	15	8	12	4	-	-	-	-	-	-	15	8	12	4	-
Southern	66	65	74	9	14%	5	4	5	1	-	60	60	69	9	15%
Total	641	631	713	82	13%	34	57	67	10	18%	592	556	633	77	14%

## Medical oncology first specialist assessments

		Тс	otal popu	llation				Māo	ri			Non-N	Māori / N	on-Pacific	
		ative num n to Octol		Differei between 20 2020	)19 and		ilative nu an to Oct		Differe between 20 2020	019 and		ative num n to Octol		Differe between 20 2020	019 and
	2018	2019	2020	Number	%	2018	2019	2020	Number	%	2018	2019	2020	Number	%
Northland	357	399	351	-48	-12%	104	103	99	-4	-4%	252	291	248	-43	-15%
Auckland	1923	1977	2150	173	9%	227	230	252	22	10%	1444	1501	1603	102	7%
Waikato	672	652	710	58	9%	143	139	152	13	9%	520	497	551	54	11%
Bay of Plenty	382	416	438	22	5%	60	101	80	-21	-21%	319	312	354	42	13%
Lakes	113	156	183	27	17%	41	53	57	4	8%	70	99	124	25	25%
Tairāwhiti	66	122	125	3	2%	31	53	52	-1	-2%	35	67	72	5	7%
Taranaki	193	210	196	-14	-7%	18	29	21	-8	-28%	173	180	174	-6	-3%
MidCentral	929	913	920	7	1%	135	152	153	1	1%	774	749	756	7	1%
Capital & Coast	748	717	732	15	2%	76	93	91	-2	-2%	629	587	592	5	1%
Nelson Marlborough	365	336	373	37	11%	24	26	19	-7	-27%	340	308	352	44	14%
West Coast	22	31	17	-14	-45%	1	5	0	-5	-	21	25	17	-8	-32%
Canterbury	1058	1107	940	-167	-15%	71	77	60	-17	-22%	974	1016	863	-153	-15%
South Canterbury	7	2	52	50	-	0	0	2	2	-	7	2	50	48	-
Southern	499	619	532	-87	-14%	23	40	29	-11	-28%	473	574	495	-79	-14%
Total	7334	7657	7719	62	1%	954	1101	1067	-34	-3%	6031	6208	6251	43	1%

## Medical oncology IV chemotherapy

		Tot	al populati	ion				Māor	i			Non-M	āori / Nor	n-Pacific	
		tive numbe to October		Differe between and 20	2019		ative num n to Octol		Differe between 20 2020	)19 and	Cumula	tive numbe to Octobe		Differ betweer and 2	n 2019
	2018	2019	2020	Number	%	2018	2019	2020	Number	%	2018	2019	2020	Number	%
Northland	2606	2456	2359	-97	-4%	567	588	732	144	24%	1999	1847	1607	-240	-13%
Waitemata	1	2	1	-1	-	-	-	-	-	-	1	2	1	-1	-
Auckland	14568	17073	18596	1523	9%	1566	1507	2096	589	39%	11431	13436	14359	923	7%
Waikato	6072	6459	5586	-873	-14%	969	1090	903	-187	-17%	5036	5291	4576	-715	-14%
Bay of Plenty	4327	4309	4793	484	11%	750	757	989	232	31%	3532	3512	3762	250	7%
Lakes	2368	2723	2614	-109	-4%	715	732	758	26	4%	1591	1962	1829	-133	-7%
Tairāwhiti	624	483	502	19	4%	252	226	230	4	2%	371	251	271	20	8%
Taranaki	1338	1578	1720	142	9%	185	122	173	51	42%	1139	1443	1528	85	6%
Whanganui	107	75	76	1	1%	18	9	9	0	-	89	66	67	1	2%
Hawke's Bay	27	43	64	21	49%	12	11	54	43	391%	15	32	10	-22	-69%
MidCentral	5550	6591	6336	-255	-4%	839	1182	1083	-99	-8%	4588	5240	5178	-62	-1%
Capital & Coast	5344	5856	5169	-687	-12%	501	665	563	-102	-15%	4610	4900	4295	-605	-12%
Hutt Valley	95	99	98	-1	-1%	13	3	8	5	-	82	83	83	0	0%
Wairarapa	29	22	63	41	186%	0	4	19	15	-	29	18	36	18	100%
Nelson Marlborough	2599	2338	2540	202	9%	189	174	99	-75	-43%	2380	2120	2419	299	14%
West Coast	11	37	29	-8	-22%	0	2	5	3	-	11	35	24	-11	-31%
Canterbury	5787	5127	5302	175	3%	370	312	354	42	13%	5255	4699	4784	85	2%
South Canterbury	873	903	906	3	0%	6	8	24	16	-	866	883	882	-1	0%
Southern	5912	6027	5682	-345	-6%	354	289	299	10	3%	5525	5684	5304	-380	-7%
Total	58238	62201	62436	235	0%	7306	7681	8398	717	9%	48550	51504	51015	-489	-1%

## Radiation oncology first specialist assessments

		Тс	otal popu	lation				Māo	ri				Non-N	/lāori / N	on-Pacific	
		ative num n to Octob		Differe between 20 2020	)19 and		llative nu an to Oct		Differe between 20 2020	)19 and			tive num to Octob		Differe between 20 2020	019 and
	2018	2019	2020	Number	%	2018	2019	2020	Number	%	_	2018	2019	2020	Number	%
Northland	296	294	237	-57	-19%	85	73	83	10	14%		206	218	152	-66	-30%
Auckland	2669	2681	2688	7	0%	313	329	316	-13	-4%		2037	2006	2083	77	4%
Waikato	1107	1183	1237	54	5%	198	204	261	57	28%		887	959	960	1	0%
Bay of Plenty	723	837	700	-137	-16%	109	126	105	-21	-17%		608	701	590	-111	-16%
Lakes	36	18	15	-3	-17%	12	6	5	-1	-		24	12	10	-2	-17%
Tairāwhiti	65	50	33	-17	-34%	27	19	18	-1	-5%		36	31	15	-16	-52%
MidCentral	1498	1370	1487	117	9%	185	187	196	9	5%		1294	1171	1272	101	9%
Capital & Coast	1156	1214	1121	-93	-8%	102	116	108	-8	-7%		1004	1049	958	-91	-9%
Nelson Marlborough	82	190	141	-49	-26%	5	10	8	-2	-20%		77	179	132	-47	-26%
West Coast	7	10	7	-3	-30%	0	1	0	-1	-		7	9	7	-2	-
Canterbury	1392	1342	1482	140	10%	75	89	67	-22	-25%		1302	1236	1395	159	13%
Southern	841	919	827	-92	-10%	46	48	59	11	23%		781	862	754	-108	-13%
Total	9872	10108	9975	-133	-1%	1157	1208	1226	18	1%		8263	8433	8328	-105	-1%

#### Radiation oncology megavoltage fractions

		Tota	al populati	on					Māori			-		Non-Ma	āori / Non-	Pacific	
		ive numbe to October		Differe between and 20	2019			ative num n to Octob		Differe betweer and 2	2019			ive numbe to October		Differe betweer and 20	2019
	2018	2019	2020	Number	%	_	2018	2019	2020	Number	%		2018	2019	2020	Number	%
Auckland	37443	38422	35119	-3303	-9%		5165	5286	4639	-647	-12%	F	28465	29257	26924	-2333	-8%
Waikato	17328	19332	16179	-3153	-16%		3479	3347	3612	265	8%		13483	15610	12337	-3273	-21%
Bay of Plenty	14416	13209	12538	-671	-5%		2551	2131	2074	-57	-3%		11684	10967	10285	-682	-6%
MidCentral	18046	19865	18781	-1084	-5%		2581	2935	2568	-367	-13%		15286	16850	15839	-1011	-6%
Capital & Coast	16168	17177	16228	-949	-6%		1825	2009	1821	-188	-9%		13621	14332	13469	-863	-6%
Nelson Marlborough	0	0	6	6	-		0	0	3	3	-		0	0	3	3	-
Canterbury	24029	19681	20498	817	4%		1669	1345	1203	-142	-11%		21899	18078	19070	992	5%
Southern	6097	4712	2774*				374	242	164	-78	-32%		5602	4422	2590	-1832	-41%
Total	133527	132398	122123	-10275	-8%	-	17644	17295	16084	-1211	-7%		110040	109516	100517	-8999	-8%

Note: there was a delay in receiving data from Southern DHB, so the 2020 total is not accurate and number and percentage changes have not been presented. After this report was finalised, late data from Southern DHB was received for this metric. The refreshed October 2020 total has increased from 2,774 to 3,558. Due to timing, the tables and graphs throughout the report were not updated.

## Haematology first specialist assessment

		Т	otal pop	ulation		_			Māo	ri				Non-N	/lāori / N	Ion-Pacific	
		lative nu an to Oct		Differe between 20 2020	019 and			lative nu an to Oct		Differe between 20 2020	)19 and			ative nu n to Oct		Differe between 20 2020	019 and
	2018	2019	2020	Number	%	_	2018	2019	2020	Number	%	201	.8	2019	2020	Number	%
Northland	173	191	232	41	21%		30	44	60	16	36%	14	1	144	169	25	17%
Waitemata	619	536	595	59	11%		34	31	38	7	23%	55	3	488	528	40	8%
Auckland	797	840	664	-176	-21%		59	68	56	-12	-18%	65	8	693	525	-168	-24%
Counties Manukau	670	573	580	7	1%		68	64	69	5	8%	49	9	421	415	-6	-1%
Waikato	557	606	599	-7	-1%		92	114	101	-13	-11%	45	7	484	489	5	1%
Bay of Plenty	320	323	282	-41	-13%		57	53	41	-12	-23%	25	8	265	238	-27	-10%
Lakes	0	2	1	-1	-		0	1	0	-1	-	0		1	1	0	-
Tairāwhiti	41	25	40	15	60%		15	6	11	5	-	26	;	18	29	11	61%
Taranaki	111	147	150	3	2%		13	13	22	9	69%	98	8	133	127	-6	-5%
MidCentral	645	656	677	21	3%		78	76	98	22	29%	55	9	573	564	-9	-2%
Capital & Coast	678	662	615	-47	-7%		41	62	65	3	5%	60	6	570	519	-51	-9%
Nelson Marlborough	152	136	96	-40	-29%		1	6	4	-2	-	15	0	128	92	-36	-28%
West Coast	11	16	6	-10	-63%		2	0	0	0	-	9		16	6	-10	-63%
Canterbury	358	453	436	-17	-4%		17	24	23	-1	-4%	33	2	414	410	-4	-1%
Southern	241	255	277	22	9%		16	16	16	0	0%	22	2	235	259	24	10%
Total	5373	5421	5250	-171	-3%		523	578	604	26	4%	456	8	4583	4371	-212	-5%

#### Haematology IV chemotherapy

		To	tal popula	ation					Māc	ori				Non-M	āori / No	on-Pacific	
		ative num n to Octol		Differe between and 20	2019			llative nu an to Oct		Differe between 2 202	019 and			ative num 1 to Octob		Differe between and 20	2019
	2018	2019	2020	Number	%	_	2018	2019	2020	Number	%	-	2018	2019	2020	Number	%
Northland	1503	1370	1060	-310	-23%		354	308	219	-89	-29%		1149	1003	796	-207	-21%
Waitemata	3443	3433	3178	-255	-7%		59	117	133	16	14%		3174	3160	2849	-311	-10%
Auckland	2950	3156	2852	-304	-10%		182	197	121	-76	-39%		2488	2605	2404	-201	-8%
Counties Manukau*	2018	1208	2162				236	153	229	76	50%		1331	881	1582	701	80%
Waikato	1662	1774	1949	175	10%		247	362	375	13	4%		1400	1410	1574	164	12%
Bay of Plenty	1106	1111	955	-156	-14%		140	73	128	55	75%		966	998	821	-177	-18%
Lakes	207	556	604	48	9%		54	161	165	4	2%		153	395	439	44	11%
Tairāwhiti	160	123	90	-33	-27%		24	10	21	11	110%		120	113	69	-44	-39%
MidCentral	2302	2291	1934	-357	-16%		277	282	150	-132	-47%		2000	2007	1763	-244	-12%
Capital & Coast	2593	2870	2833	-37	-1%		78	390	321	-69	-18%		2393	2413	2210	-203	-8%
Nelson Marlborough	4	1	10	9	-		1	0	0	0	-		3	1	10	9	-
West Coast	6	16	9	-7	-44%		1	3	0	-3	-		5	13	9	-4	-31%
Canterbury*	1690	1552	2275				133	121	214	93	77%		1540	1413	2018	605	43%
Southern**	179	204	545	341	167%		1	7	39	32	-		178	197	501	304	154%
Total	19823	19665	20456	791	4%	-	1787	2184	2115	-69	-3%		16900	16609	17045	436	3%

\*Te Aho o Te Kahu continues to work with Canterbury and Counties DHBs to better understand and improve quality of data in 2019. Number and percentage differences have not been presented as will not accurately reflect the difference between 2019 and 2020 in these DHBs.

\*\* Note the relatively low volumes in Southern DHB are due to variation in coding.

# **Appendix 4: Surgical procedure codes**

Below is a list of the surgical procedure codes that were used for analysis on curative cancer surgery.

	COLORECTAL CANCER SURGERY				
Clinical code	Block short description	Clinical code description			
3200000	Colectomy	Limited excision of large intestine with formation of stoma			
3200001	Colectomy	Right hemicolectomy with formation of stoma			
3200300	Colectomy	Limited excision of large intestine with anastomosis			
3200301	Colectomy	Right hemicolectomy with anastomosis			
3200400	Colectomy	Subtotal colectomy with formation of stoma			
3200401	Colectomy	Extended right hemicolectomy with formation of stoma			
3200500	Colectomy	Subtotal colectomy with anastomosis			
3200501	Colectomy	Extended right hemicolectomy with anastomosis			
3200600	Colectomy	Left hemicolectomy with anastomosis			
3200601	Colectomy	Left hemicolectomy with formation of stoma			
3200900	Colectomy	Total colectomy with ileostomy			
3201200	Colectomy	Total colectomy with ileorectal anastomosis			
3201500	Total proctocolectomy	Total proctocolectomy with ileostomy			
3202400	Anterior resection of rectum	High anterior resection of rectum			
3202500	Anterior resection of rectum	Low anterior resection of rectum			
3202600	Anterior resection of rectum	Ultra low anterior resection of rectum			
3202800	Anterior resection of rectum	Ultra low anterior resection of rectum with hand sutured coloanal anastomosis			
3203000	Rectosigmoidectomy or proctectomy	Rectosigmoidectomy with formation of stoma			
3203900	Rectosigmoidectomy or proctectomy	Abdominoperineal proctectomy			
3205100	Total proctocolectomy	Total proctocolectomy with ileo-anal anastomosis			
3205101	Total proctocolectomy	Total proctocolectomy with ileo-anal anastomosis and formation of temporary ileostomy			
3206000	Rectosigmoidectomy or proctectomy	Restorative proctectomy			
3209900	Excision of lesion or tissue of rectum or anus	Per anal submucosal excision of lesion or tissue of rectum			
3211200	Rectosigmoidectomy or proctectomy	Perineal rectosigmoidectomy			
9220800	Anterior resection of rectum	Anterior resection of rectum, level unspecified			

LUNG CANCER SURGERY				
Clinical code	Clinical code description	Block Description		
3844000	Wedge resection of lung	Partial resection of lung		
3844001	Radical wedge resection of lung	Partial resection of lung		
3843800	Segmental resection of lung	Partial resection of lung		
9016900	Endoscopic wedge resection of lung	Partial resection of lung		

3843801	Lobectomy of lung	Lobectomy of lung
3844100	Radical lobectomy	Lobectomy of lung
3844101	Radical pneumonectomy	Pneumonectomy
3843802	Pneumonectomy	Pneumonectomy

PROSTATE CANCER SURGERY				
Clinical code	Block short description	Clinical code description		
3720004	Open prostatectomy	Retropubic prostatectomy		
3720900	Open prostatectomy	Radical prostatectomy		
3720901	Other closed prostatectomy	Laparoscopic radical prostatectomy		
3721000	Open prostatectomy	Radical prostatectomy with bladder neck reconstruction		
3721001	Other closed prostatectomy	Laparoscopic radical prostatectomy with bladder neck reconstruction		
3721100	Open prostatectomy	Radical prostatectomy with bladder neck reconstruction and pelvic lymphadenectomy		
3721101	Other closed prostatectomy	Laparoscopic radical prostatectomy with bladder neck reconstruction and pelvic lymphadenectomy		
3720900	Open prostatectomy	Radical prostatectomy		
3720901	Closed prostatectomy	Laparoscopic radical prostatectomy		
3721000	Open prostatectomy	Radical prostatectomy with bladder neck reconstruction		
3721001	Closed prostatectomy	Laparoscopic radical prostatectomy with bladder neck reconstruction		
3721100	Open prostatectomy	Radical prostatectomy with bladder neck reconstruction and pelvic lymphadenectomy		